Journal of the National Comprehensive Cancer Network · 2014 · 72 citations · 15 references
Life SciencesEndocrinologyImmunologyImmunotherapyInflammationTumor ImmunologyAutoimmune DiseasesImmune-related Adverse EventsImmunosuppressionCytotoxic T Lymphocyte Antigen 4Dermatologic Adverse EventsHypophysitis ImagingImmune-mediated Adverse EventsImmune-related Skin ToxicityInjection-related Adverse EventsMetastatic Melanoma TreatmentPituitary Physiology
Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4, leading to enhanced T-cell activation and proliferation, is associated with improved overall survival in melanoma. Its use can result in immune-related adverse events, the most common of which are skin rash, diarrhea, and colitis. Ipilimumab-induced hypophysitis is uncommon, mostly involves anterior pituitary, and is associated with abnormalities in pituitary MRI, whereas uveitis has been rarely reported. These immune-related adverse events occur during therapy. This report describes a patient who developed uveitis and hypophysitis involving both anterior and posterior pituitary, without MRI findings more than 3 weeks after the fourth dose of ipilimumab. This case illustrates the unusual presentation of and diagnostic challenges associated with ipilimumab-induced immune-related adverse events.
15
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin, Marc S. Ernstoff, Omid Hamid et al. · The Lancet Oncology · 2012 · 1.1K citations
Medicine, Oncology, Pharmacology +12